Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEMOIMMUNE: Pembrolizumab + Cyclophosphamide in Metastatic Breast Cancer
NCT03139851Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by Centre Léon Bérard. Primary endpoints: Severe Toxicities in Run-In Phase at 6 weeks and Clinical Benefit Rate at 24 weeks. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03139851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139851.